The FDA has approved Celgene's supplemental new drug application for ABRAXANE, a pancreatic cancer treatment.
In combination with gemcitabine, ABRAXANE is a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, which accounts for about 95 percent of all pancreatic cancers.
The approval is based on results from the Metastic Pancreatic Adenocarcinoma Clinical Trial, a randomized, international study.
More Articles on Gastroenterology:
Drs. Renjy Vattasseril, Anthony Masciarelli Join Cape Regional Physicians Associates
NIH Grants Medical College of Wisconsin $2M to Study GERD
Probiotics May Not Prevent Crohn's Disease Relapses, Study Says
In combination with gemcitabine, ABRAXANE is a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, which accounts for about 95 percent of all pancreatic cancers.
The approval is based on results from the Metastic Pancreatic Adenocarcinoma Clinical Trial, a randomized, international study.
More Articles on Gastroenterology:
Drs. Renjy Vattasseril, Anthony Masciarelli Join Cape Regional Physicians Associates
NIH Grants Medical College of Wisconsin $2M to Study GERD
Probiotics May Not Prevent Crohn's Disease Relapses, Study Says